Cargando…

A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression

In the absence of head-to-head trials of first-line treatments for metastatic non-small cell lung cancer (NSCLC), synthesis of available evidence is needed. We conducted a systematic literature review and network meta-analysis of randomized controlled trials in patients with stage IV NSCLC and high...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbst, Roy, Jassem, Jacek, Abogunrin, Seye, James, Daniel, McCool, Rachael, Belleli, Rossella, Giaccone, Giuseppe, De Marinis, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300186/
https://www.ncbi.nlm.nih.gov/pubmed/34307144
http://dx.doi.org/10.3389/fonc.2021.676732
_version_ 1783726414066876416
author Herbst, Roy
Jassem, Jacek
Abogunrin, Seye
James, Daniel
McCool, Rachael
Belleli, Rossella
Giaccone, Giuseppe
De Marinis, Filippo
author_facet Herbst, Roy
Jassem, Jacek
Abogunrin, Seye
James, Daniel
McCool, Rachael
Belleli, Rossella
Giaccone, Giuseppe
De Marinis, Filippo
author_sort Herbst, Roy
collection PubMed
description In the absence of head-to-head trials of first-line treatments for metastatic non-small cell lung cancer (NSCLC), synthesis of available evidence is needed. We conducted a systematic literature review and network meta-analysis of randomized controlled trials in patients with stage IV NSCLC and high programmed death-ligand 1 (PD-L1) expression. Patients with other-stage NSCLC or without PD-L1 expression and populations with < 80% stage IV NSCLC were excluded. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events. English records from MEDLINE and Embase published through October 2020 were eligible, supplemented by hand searches of other sources. Three evidence networks were constructed based on histology (mixed, squamous, non-squamous). OS and PFS results were analyzed applying Bayesian fractional polynomial random-effects models. Hazard ratios over time with 95% credible intervals (CrIs) and expected differences in OS and PFS between each cancer immunotherapy regimen and the chemotherapy common comparator were generated. Seventeen clinical trials were included after screening 32,527 records. Heterogeneity and risk of bias were generally low across trials. In the mixed-histology network of PD-L1–high patients, expected OS was significantly longer with atezolizumab (estimated difference: 10.4 months [95% CrI: 1.9, 18.2]), pembrolizumab (7.2 [2.2, 12.3]), and cemiplimab (13.0 [4.2, 21.0]) versus chemotherapy but not with nivolumab (3.5 [−2.5, 10.6]) or nivolumab plus ipilimumab (6.7 [−0.5, 14.2]) versus chemotherapy. OS improvements were not significant compared with chemotherapy for any regimen in the squamous and non-squamous networks, except pembrolizumab plus chemotherapy in the non-squamous network. All regimens showed significantly longer expected PFS versus chemotherapy in the non-squamous network, whereas the increases were not significant in the mixed or squamous networks. ORR was significantly higher with pembrolizumab and cemiplimab versus chemotherapy in the mixed-histology network, with sintilimab in the non-squamous network, and with combination regimens, including pembrolizumab or atezolizumab, in the squamous and non-squamous networks, except with atezolizumab plus carboplatin, paclitaxel, and bevacizumab. Survival and safety versus chemotherapy were generally similar across cancer immunotherapies and histology networks. These findings may support treatment decisions for patients with high PD-L1 status receiving first-line treatment for NSCLC.
format Online
Article
Text
id pubmed-8300186
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83001862021-07-24 A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression Herbst, Roy Jassem, Jacek Abogunrin, Seye James, Daniel McCool, Rachael Belleli, Rossella Giaccone, Giuseppe De Marinis, Filippo Front Oncol Oncology In the absence of head-to-head trials of first-line treatments for metastatic non-small cell lung cancer (NSCLC), synthesis of available evidence is needed. We conducted a systematic literature review and network meta-analysis of randomized controlled trials in patients with stage IV NSCLC and high programmed death-ligand 1 (PD-L1) expression. Patients with other-stage NSCLC or without PD-L1 expression and populations with < 80% stage IV NSCLC were excluded. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events. English records from MEDLINE and Embase published through October 2020 were eligible, supplemented by hand searches of other sources. Three evidence networks were constructed based on histology (mixed, squamous, non-squamous). OS and PFS results were analyzed applying Bayesian fractional polynomial random-effects models. Hazard ratios over time with 95% credible intervals (CrIs) and expected differences in OS and PFS between each cancer immunotherapy regimen and the chemotherapy common comparator were generated. Seventeen clinical trials were included after screening 32,527 records. Heterogeneity and risk of bias were generally low across trials. In the mixed-histology network of PD-L1–high patients, expected OS was significantly longer with atezolizumab (estimated difference: 10.4 months [95% CrI: 1.9, 18.2]), pembrolizumab (7.2 [2.2, 12.3]), and cemiplimab (13.0 [4.2, 21.0]) versus chemotherapy but not with nivolumab (3.5 [−2.5, 10.6]) or nivolumab plus ipilimumab (6.7 [−0.5, 14.2]) versus chemotherapy. OS improvements were not significant compared with chemotherapy for any regimen in the squamous and non-squamous networks, except pembrolizumab plus chemotherapy in the non-squamous network. All regimens showed significantly longer expected PFS versus chemotherapy in the non-squamous network, whereas the increases were not significant in the mixed or squamous networks. ORR was significantly higher with pembrolizumab and cemiplimab versus chemotherapy in the mixed-histology network, with sintilimab in the non-squamous network, and with combination regimens, including pembrolizumab or atezolizumab, in the squamous and non-squamous networks, except with atezolizumab plus carboplatin, paclitaxel, and bevacizumab. Survival and safety versus chemotherapy were generally similar across cancer immunotherapies and histology networks. These findings may support treatment decisions for patients with high PD-L1 status receiving first-line treatment for NSCLC. Frontiers Media S.A. 2021-07-09 /pmc/articles/PMC8300186/ /pubmed/34307144 http://dx.doi.org/10.3389/fonc.2021.676732 Text en Copyright © 2021 Herbst, Jassem, Abogunrin, James, McCool, Belleli, Giaccone and De Marinis https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Herbst, Roy
Jassem, Jacek
Abogunrin, Seye
James, Daniel
McCool, Rachael
Belleli, Rossella
Giaccone, Giuseppe
De Marinis, Filippo
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
title A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
title_full A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
title_fullStr A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
title_full_unstemmed A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
title_short A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
title_sort network meta-analysis of cancer immunotherapies versus chemotherapy for first-line treatment of patients with non-small cell lung cancer and high programmed death-ligand 1 expression
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300186/
https://www.ncbi.nlm.nih.gov/pubmed/34307144
http://dx.doi.org/10.3389/fonc.2021.676732
work_keys_str_mv AT herbstroy anetworkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT jassemjacek anetworkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT abogunrinseye anetworkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT jamesdaniel anetworkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT mccoolrachael anetworkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT bellelirossella anetworkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT giacconegiuseppe anetworkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT demarinisfilippo anetworkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT herbstroy networkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT jassemjacek networkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT abogunrinseye networkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT jamesdaniel networkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT mccoolrachael networkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT bellelirossella networkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT giacconegiuseppe networkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression
AT demarinisfilippo networkmetaanalysisofcancerimmunotherapiesversuschemotherapyforfirstlinetreatmentofpatientswithnonsmallcelllungcancerandhighprogrammeddeathligand1expression